Iris Najjar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Iris Najjar has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Camila de Paula Siqueira
Laboratório Alerta, Division of Infectious Diseases, Escola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, Brazil; Antimicrobial Resistance Institute of São Paulo (ARIES), Universidade Federal de São Paulo, São Paulo, Brazil
3 shared publicationsCelso Arrais-Rodrigues
Division of Hematology, Escola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, Brazil
3 shared publications- Jôiciglecia Pereira dos Santos
Laboratório Alerta, Division of Infectious Diseases (IN, LSG, JPS, CPS, MBI, ACSR, ACG), Escola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, Brazil; Antimicrobial Resistance Institute of São Paulo (ARIES) (IN, JPS, CPS, MBI, ACSR, ACG), Universidade Federal de São Paulo, São Paulo, Brazil
3 shared publications Larissa Simão Gandolpho
Laboratório Alerta, Division of Infectious Diseases, Escola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, Brazil; Antimicrobial Resistance Institute of São Paulo (ARIES), Universidade Federal de São Paulo, São Paulo, Brazil; Division of Infectious Diseases, Escola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, Brazil; Division of Hematology, Escola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, Brazil
3 shared publicationsRoberto Sierra
Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
3 shared publications- Ana Christina Gales
Universidade Federal de São Paulo
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in Scientific Reports
Phage heteroresistance in clinical Klebsiella pneumoniae isolates: impact of differentiated capsule expression on phage efficacy
Heteroresistance, commonly described in the context of antibiotics, refers to the presence of resistant subpopulations within a bacterial strain, and is recognized as a likely contributor to treatment failure. Whether population heterogeneity affects phage activity remains poorly understood. We investigated whether heterogeneity in clinical, mostly multidrug-resistant Klebsiella pneumoniae (Kpn) isolates contributes to phage heteroresistance, focusing on the role of capsule-deficient subpopulations. We isolated and characterized 23 strictly lytic phages against diverse clinical Kpn strains. Host range revealed phages with varying spectra, one able to infect up to four different sequence types and two capsule loci. Most phages surprisingly led to longer bacterial growth inhibition at lower multiplicity of infection (MOI). Half of the Kpn samples harboured capsule-deficient variants. Sequencing revealed the presence of insertion sequences in capsule biosynthesis or regulation genes suggesting impaired capsule production. Spot-test assays showed complete loss or reduced activity on these variants. Interestingly, reduced activity by spot-test translated into a delayed onset of infection in kinetic assays, suggesting only partial capsule-dependence for successful infection. Our findings show that lower MOI led to higher virulence in most phages, that capsule-deficient Kpn subpopulations were common, and that capsule loss significantly altered phage activity. Although the clinical implications of phage heteroresistance remain unclear, this phenomenon should be considered when designing personalized phage therapies, as it may explain treatment failure or predict the early emergence of phage-resistant mutants.
- 29 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessPhage heteroresistance in clinical Klebsiella pneumoniae isolates: impact of differentiated capsule expression on phage efficacy
Heteroresistance, commonly described in the context of antibiotics, refers to the presence of resistant subpopulations within a bacterial strain, and is recognized as a likely contributor to treatment failure. Whether population heterogeneity affects phage activity remains poorly understood. We investigated whether heterogeneity in clinical, mostly multidrug-resistant Klebsiella pneumoniae (Kpn) isolates contributes to phage heteroresistance, focusing on the role of capsule-deficient subpopulations. We isolated and characterized 23 strictly lytic phages against diverse clinical Kpn strains. Host range revealed phages with varying spectra, one able to infect up to four different sequence types and two capsule loci. Most phages surprisingly led to longer bacterial growth inhibition at lower multiplicity of infection (MOI). Half of the Kpn samples harboured capsule-deficient variants. Sequencing revealed the presence of insertion sequences in capsule biosynthesis or regulation genes suggesting impaired capsule production. Spot-test assays showed complete loss or reduced activity on these variants. Interestingly, reduced activity by spot-test translated into a delayed onset of infection in kinetic assays, suggesting only partial capsule-dependence for successful infection. Our findings show that lower MOI led to higher virulence in most phages, that capsule-deficient Kpn subpopulations were common, and that capsule loss significantly altered phage activity. Although the clinical implications of phage heteroresistance remain unclear, this phenomenon should be considered when designing personalized phage therapies, as it may explain treatment failure or predict the early emergence of phage-resistant mutants.
- 2 April 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (5) , 107766
Corrigendum to “Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol - A prospective feasibility and proof of concept study in the Brazilian context” [International Journal of Antimicrobial Agents Volume 67(2026)107673]
- 2 April 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (5) , 107766
Corrigendum to “Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol - A prospective feasibility and proof of concept study in the Brazilian context” [International Journal of Antimicrobial Agents Volume 67(2026)107673]
- 19 March 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (6) , 107788
In Reply to the Letter to Editor Regarding "Phage Therapy for KPC-Producing Klebsiella pneumoniae Decolonization in High-Risk Patients: The KIDNAP Study Protocol - A Prospective Feasibility and Proof of Concept Study in the Brazilian Context"
- 19 March 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (6) , 107788
In Reply to the Letter to Editor Regarding "Phage Therapy for KPC-Producing Klebsiella pneumoniae Decolonization in High-Risk Patients: The KIDNAP Study Protocol - A Prospective Feasibility and Proof of Concept Study in the Brazilian Context"
- Open Access
- 21 November 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (1) , 107673
Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol – A prospective feasibility and proof of concept study in the Brazilian context
- 21 November 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (1) , 107673
Open AccessPhage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol – A prospective feasibility and proof of concept study in the Brazilian context
- Open Access
- 19 August 2025
- Published by Elsevier in CMI Communications
- Vol. 2 (4)
Phage research in South America: A descriptive overview of trends and gaps
- 19 August 2025
- Published by Elsevier in CMI Communications
- Vol. 2 (4)
Open AccessPhage research in South America: A descriptive overview of trends and gaps
- Open Access
- 1 December 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1 (10)
“Trench Foot” on the Banks of Lake Geneva: A Severe Case of Nonfreezing Cold Injury
Formerly known as “trench foot” or “immersion foot,” nonfreezing cold injury (NFCI) is a rare condition mainly seen among vulnerable groups. We report the case of a homeless male diagnosed with NFC...
- 1 December 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1 (10)
Open Access“Trench Foot” on the Banks of Lake Geneva: A Severe Case of Nonfreezing Cold Injury
Formerly known as “trench foot” or “immersion foot,” nonfreezing cold injury (NFCI) is a rare condition mainly seen among vulnerable groups. We report the case of a homeless male diagnosed with NFC...
- Open Access
Prevalence and forms of gender discrimination and sexual harassment among medical students and physicians in French-speaking Switzerland: a survey
Objectives: The aim of this study was to determine the prevalence and forms of gender discrimination and sexual harassment experienced by medical students and physicians in French-speaking part of Switzerland. Design and setting: We conducted an online survey using a questionnaire of 9 multiple-choice and 2 open questions between 24 January 2019 and 24 February 2019. Our target population was medical students and physicians working at hospitals and general practitioners from the French-speaking part of Switzerland. The online survey was sent via social media platforms and direct emails. We compared answers between male-determined and female-determined respondents using either χ 2 or Fisher’s exact tests. Results: Among 1071 responders, a total of 893 were included (625 females, 264 males, 4 non-binary and 1 non-binary and male). 178 were excluded because they did not mention their working place or were working only outside Switzerland. Because of the small number of non-binary participants, they were not contemplated in further statistical analysis. Of 889 participants left, 199 (31.8%) women and 18 (6.8%) men reported having personally experienced gender discrimination, in terms of sexism, difficulties in career development and psychological pressure. Among women, senior attendings were the most affected (55.2%), followed by residents (44.1%) and junior attendings (41.1%). Sexual harassment was equally observed among women (19.0%) and men (16.7%). Compared with men (47.0%), women (61.4%) expressed the need to promote equality and inclusivity in medicine more frequently (p<0.001), as well as the need for support in their professional development (38.7% women and 23.9% men; p<0.001). Conclusions: Gender discrimination in medicine in French-speaking Switzerland affects one-third of women, in particular, those working in hospital settings and senior positions.
Open AccessPrevalence and forms of gender discrimination and sexual harassment among medical students and physicians in French-speaking Switzerland: a survey
Objectives: The aim of this study was to determine the prevalence and forms of gender discrimination and sexual harassment experienced by medical students and physicians in French-speaking part of Switzerland. Design and setting: We conducted an online survey using a questionnaire of 9 multiple-choice and 2 open questions between 24 January 2019 and 24 February 2019. Our target population was medical students and physicians working at hospitals and general practitioners from the French-speaking part of Switzerland. The online survey was sent via social media platforms and direct emails. We compared answers between male-determined and female-determined respondents using either χ 2 or Fisher’s exact tests. Results: Among 1071 responders, a total of 893 were included (625 females, 264 males, 4 non-binary and 1 non-binary and male). 178 were excluded because they did not mention their working place or were working only outside Switzerland. Because of the small number of non-binary participants, they were not contemplated in further statistical analysis. Of 889 participants left, 199 (31.8%) women and 18 (6.8%) men reported having personally experienced gender discrimination, in terms of sexism, difficulties in career development and psychological pressure. Among women, senior attendings were the most affected (55.2%), followed by residents (44.1%) and junior attendings (41.1%). Sexual harassment was equally observed among women (19.0%) and men (16.7%). Compared with men (47.0%), women (61.4%) expressed the need to promote equality and inclusivity in medicine more frequently (p<0.001), as well as the need for support in their professional development (38.7% women and 23.9% men; p<0.001). Conclusions: Gender discrimination in medicine in French-speaking Switzerland affects one-third of women, in particular, those working in hospital settings and senior positions.
- 1 July 2020
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 87, 111-112
Guillain-Barré syndrome as a complication of SARS-CoV-2 infection
- 1 July 2020
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 87, 111-112
Guillain-Barré syndrome as a complication of SARS-CoV-2 infection
- Open Access
- 17 June 2020
- Published by EMH Swiss Medical Publishers, Ltd. in Bulletin des Médecins Suisses
- Vol. 101 (2526) , 828
Comment le Covid-19 a boulevers mon mtier
- 17 June 2020
- Published by EMH Swiss Medical Publishers, Ltd. in Bulletin des Médecins Suisses
- Vol. 101 (2526) , 828
Open AccessComment le Covid-19 a boulevers mon mtier
- Open Access
- 18 February 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (2) , 553
Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature
Recurrent Campylobacter enteritis is a well-recorded complication of primary hypogammaglobulinemia but has only rarely been reported with other types of immunodeficiency, and no cases have been reported after rituximab-associated secondary hypogammaglobulinemia. We therefore reviewed our local microbiology laboratory databases and conducted a literature search, to provide a detailed characterization of the immunodeficiency states associated with recurrent Campylobacter enteritis. Published cases had primary hypogammaglobulinemia, most frequently in the setting of common variable immunodeficiency, x-linked agammaglobulinemia, and Good syndrome. No cases were identified in the literature after rituximab or secondary hypogammaglobulinemia. We report a 73-year-old patient with recurrent Campylobacter enteritis and hypogammaglobulinemia in the setting of non-Hodgkin lymphoma, chemotherapy, and maintenance rituximab. Physicians should be aware of the association of recurrent Campylobacter enteritis and immunodeficiency, most commonly in primary hypogammaglobulinemia. Rituximab alone may not be sufficiently immunosuppressive for recurrent campylobacteriosis to occur; additional factors, including hematological malignancy and its treatment, appear necessary. Patients with recurrent Campylobacter enteritis and those starting rituximab should be investigated for hypogammaglobulinemia and B-lymphopenia.
- 18 February 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (2) , 553
Open AccessRecurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature
Recurrent Campylobacter enteritis is a well-recorded complication of primary hypogammaglobulinemia but has only rarely been reported with other types of immunodeficiency, and no cases have been reported after rituximab-associated secondary hypogammaglobulinemia. We therefore reviewed our local microbiology laboratory databases and conducted a literature search, to provide a detailed characterization of the immunodeficiency states associated with recurrent Campylobacter enteritis. Published cases had primary hypogammaglobulinemia, most frequently in the setting of common variable immunodeficiency, x-linked agammaglobulinemia, and Good syndrome. No cases were identified in the literature after rituximab or secondary hypogammaglobulinemia. We report a 73-year-old patient with recurrent Campylobacter enteritis and hypogammaglobulinemia in the setting of non-Hodgkin lymphoma, chemotherapy, and maintenance rituximab. Physicians should be aware of the association of recurrent Campylobacter enteritis and immunodeficiency, most commonly in primary hypogammaglobulinemia. Rituximab alone may not be sufficiently immunosuppressive for recurrent campylobacteriosis to occur; additional factors, including hematological malignancy and its treatment, appear necessary. Patients with recurrent Campylobacter enteritis and those starting rituximab should be investigated for hypogammaglobulinemia and B-lymphopenia.